Tick-Borne Disease Panel Testing for Dogs: PCR vs Serology Diagnostic Guide

Tick-Borne Disease Testing in Dogs: Why a Panel Approach Is Essential

Tick-borne disease in dogs is a multi-pathogen problem masquerading as a single diagnosis. A dog presenting with acute fever, thrombocytopenia, and lethargy could have Ehrlichia canis monocytic ehrlichiosis, Anaplasma phagocytophilum granulocytic anaplasmosis, Babesia canis hemolytic anemia — or a co-infection of two or more simultaneously. Ixodes, Amblyomma, Rhipicephalus, and Dermacentor ticks commonly carry multiple pathogens, and single-agent testing misses the co-infections that worsen outcomes and complicate treatment.

Canine tick panel testing — a single test run that screens for Ehrlichia spp., Anaplasma spp., Borrelia burgdorferi (Lyme disease), and Babesia spp. in parallel — is now the clinical standard for any dog with fever, thrombocytopenia, anemia, polyarthritis, or recent tick exposure. This guide provides the diagnostic framework veterinary clinicians need to order the right tests, interpret results with confidence, and act on findings without delay.

For an overview of our portable molecular diagnostic platform, see our CarryOn test chip products and the technology behind microfluidic PCR.

Pathogen Overview: What Ticks Carry and When

Understanding the biology of each pathogen is the foundation of rational test selection and result interpretation.

Ehrlichia canis (Canine Monocytic Ehrlichiosis — CME)

*E. canis* is transmitted by the brown dog tick (*Rhipicephalus sanguineus*) and is globally distributed wherever this tick is endemic. The organism is an obligate intracellular bacterium that infects mononuclear cells (monocytes and lymphocytes). Clinical stages are classically divided into:

• Acute phase (1–4 weeks post-infection): Fever (39.5–41°C), lethargy, anorexia, lymphadenopathy, thrombocytopenia (platelet counts typically 50,000–100,000/µL)
• Subclinical phase (weeks to months): Clinically inapparent but thrombocytopenia and antibody positivity persist
• Chronic phase: Pancytopenia, hyperglobulinemia, epistaxis, retinal hemorrhage — associated with high morbidity

Incubation period: 8–20 days post-tick bite. Antibodies appear 7–28 days post-exposure (seroconversion window). PCR becomes positive during the acute febrile phase, typically days 4–10 of illness.

Anaplasma phagocytophilum (Canine Granulocytic Anaplasmosis — CGA)

Transmitted by *Ixodes scapularis* (black-legged tick) in the eastern US and *Ixodes pacificus* on the West Coast — the same tick vectors that transmit Lyme disease. This co-vector relationship makes Anaplasma-Borrelia co-infection common in endemic areas.

*A. phagocytophilum* infects neutrophils. Morulae (intracytoplasmic inclusion bodies) visible on blood smear in 20–50% of acute cases are pathognomonic but require experienced interpretation. Clinical presentation mirrors CME: fever, lethargy, thrombocytopenia, anorexia, and occasionally polyarthritis.

Incubation period: 1–2 weeks. PCR becomes positive 24–48 hours after infection, well before antibody seroconversion.

Borrelia burgdorferi (Canine Lyme Disease)

Transmitted by *Ixodes* ticks (primarily *I. scapularis* in the northeast and upper midwest US). Tick attachment duration of at least 36–48 hours is required for transmission. Unlike in humans, the classic expanding skin lesion (erythema migrans) is rarely observed in dogs.

Most infected dogs remain subclinical. A subset develop:

• Lyme arthritis: Shifting-leg lameness, joint swelling, fever — typically appears 2–5 months post-infection
• Lyme nephropathy: Protein-losing nephropathy; Labrador and Golden Retrievers appear overrepresented; associated with high mortality

Seroconversion window: 3–5 weeks post-infection. Antibodies against the C6 peptide (the most diagnostically specific Lyme antigen) appear 3–6 weeks post-exposure. PCR sensitivity for *B. burgdorferi* in blood is notably lower than for Ehrlichia/Anaplasma (blood spirochetemia is transient); skin biopsy or synovial fluid PCR is more sensitive for confirmation of active disease.

Babesia spp. (Canine Babesiosis)

Babesia are intraerythrocytic protozoan parasites transmitted by tick bite, blood transfusion, or vertical transmission. Two primary species in North American dogs:

• Babesia canis vogeli: Transmitted by *R. sanguineus*; tends to produce milder hemolysis; common in southern US
• Babesia gibsoni: Transmitted by *Haemaphysalis longicornis* and potentially dog bite wounds (high prevalence in American Pit Bull Terriers); small form, harder to detect on smear; associated with more severe, chronic hemolytic anemia

Incubation period: 10–21 days. Parasitemia detectable by blood smear in 20–40% of cases during the acute phase; PCR is significantly more sensitive.

PCR vs Serology: The Core Diagnostic Distinction

The choice between PCR and serology is not a matter of preference — it is a matter of what clinical question you are asking.

Key clinical rule: For an acutely ill febrile dog in the first 1–2 weeks of illness, PCR is the appropriate first-line test. For a dog with vague chronic signs or suspected past exposure in an endemic area, serology (SNAP 4Dx Plus or equivalent) may be more sensitive due to persistent antibody titers.

Pathogen-by-Pathogen Comparison: PCR vs SNAP/ELISA

Why Babesia Serology Underperforms

Babesia serology cross-reactivity between species is significant, and commercially available in-clinic ELISA kits do not reliably distinguish *B. canis* from *B. gibsoni* — which matters because treatment protocols differ. Imidocarb dipropionate is effective for *B. canis vogeli* but has poor efficacy against *B. gibsoni* (which requires atovaquone plus azithromycin). PCR with species-level identification is essential for Babesia to guide correct treatment selection.

Understanding Ct Values in Tick-Borne Disease PCR

Quantitative PCR reports a cycle threshold (Ct value) — the number of amplification cycles required to produce a detectable fluorescent signal. Ct values carry critical clinical information that serology cannot provide:

• Ct ≤ 28: High pathogen burden — acute active infection; immediate treatment indicated
• Ct 29–34: Moderate burden — consistent with early or subacute infection; treat promptly
• Ct 35–38: Low burden — early infection, post-treatment residual, or subclinical carrier state; clinical context essential
• Ct > 38 or undetermined: Below detection threshold for that sample — consider serology if clinical suspicion remains

Using Ct to monitor treatment response:

For Ehrlichia and Anaplasma, doxycycline (10 mg/kg PO q24h for 28 days) produces a rapid reduction in bacterial load. Serial PCR at day 7 and day 28 of treatment should show rising Ct values (lower pathogen burden). Persistently low Ct values at day 14 suggest treatment failure, possible doxycycline resistance, re-exposure, or co-infection with an untreated pathogen.

The CarryOn microfluidic PCR platform reports quantitative Ct values for each target in the tick panel, enabling serial monitoring without sending samples to a reference laboratory. Learn more about the underlying PCR technology.

Co-Infection: The Rule, Not the Exception in Tick-Endemic Regions

Regional tick surveillance studies demonstrate that 10–30% of *Ixodes scapularis* ticks in hyperendemic northeastern US counties carry more than one pathogen. Clinical implications of co-infection:

• Ehrlichia + Babesia: Combined thrombocytopenia from CME and hemolytic anemia from Babesia causes severe anemia; higher transfusion requirement; higher mortality
• Anaplasma + Borrelia: Common in Ixodes-endemic regions; Lyme arthritis may be masked by acute Anaplasma febrile illness
• Ehrlichia + Anaplasma: Both require doxycycline; however, thrombocytopenia may be more severe in co-infected dogs
• Babesia gibsoni + any co-pathogen: Treatment protocol for *B. gibsoni* differs significantly from Ehrlichia/Anaplasma; a missed Babesia diagnosis means delayed species-specific therapy

Panel testing — running Ehrlichia, Anaplasma, Borrelia, and Babesia simultaneously — eliminates the diagnostic gap that single-agent testing creates. Every dog with suspected tick-borne disease should receive a full panel.

Clinical Staging and When to Test

Acute Presentation (Days 1–14)

A dog with acute fever (≥39.5°C), lethargy, anorexia, and thrombocytopenia within 2–4 weeks of known or suspected tick exposure is an ideal candidate for PCR panel testing. Pathogen DNA is present in circulation at detectable levels; serology may be negative because antibodies have not yet developed.

Minimum CBC findings suggesting tick-borne disease:

• Thrombocytopenia: platelet count < 150,000/µL (most sensitive single finding)
• Leukopenia or neutropenia (Ehrlichia, Anaplasma)
• Non-regenerative anemia (Ehrlichia chronic)
• Hemolytic anemia with spherocytosis (Babesia)

Subacute Presentation (Days 14–60)

Dogs presenting 2–8 weeks after exposure may have partially seroconverted. A combined approach — both serology (SNAP 4Dx Plus) and PCR — provides maximum sensitivity. The SNAP captures antibodies from pathogens where PCR sensitivity has declined as bacteremia resolves; PCR catches active infections where antibody titers are still rising.

Chronic or Screening Presentation

For dogs with vague chronic signs (intermittent lethargy, weight loss, hyperglobulinemia, epistaxis) or in endemic-area wellness screening, serology is the primary test. Antibodies persist for months to years and remain elevated long after pathogen burden has dropped below PCR detection thresholds.

Geographic Considerations: Where to Suspect Which Pathogens

Dogs with travel history or those recently imported require extended panel testing — *Ehrlichia canis* is hyperendemic in parts of Southeast Asia, Central America, and Southern Europe.

Sample Collection Protocol for Tick-Borne Disease PCR

Correct sample collection is the single most controllable variable in PCR diagnostic accuracy.

Blood collection:

• Use an EDTA (purple top) tube — heparin (green top) inhibits Taq polymerase and causes false negatives
• Collect 1–3 mL whole blood; invert tube 8–10 times gently to mix with anticoagulant
• Do not centrifuge — PCR for Ehrlichia and Anaplasma targets white blood cells (buffy coat), and Babesia targets red blood cells; separation removes the cellular target
• Test within 24 hours of collection (stored at 2–8°C); do not freeze whole blood

Blood smear (complementary to PCR):

• Prepare within 30 minutes of collection for best cell morphology
• Examine 200 fields at 100× oil immersion for morulae (*Ehrlichia*, *Anaplasma*) and piroplasms (*Babesia*)
• Smear sensitivity: ~20–50% for morulae detection; ~20–40% for Babesia in low-parasitemia cases
• PCR detects what smear misses — always run both in acute cases

For the CarryOn tick panel chip: Load 100 µL of whole blood directly into the chip input well. The integrated microfluidic system performs lysis, nucleic acid extraction, and multiplex PCR amplification without manual pipetting steps. Results are reported in under 60 minutes with individual Ct values for each pathogen target.

For detailed sample handling guidance, see our veterinary sample collection and handling guide.

Interpreting Tick Panel Results: A Decision Framework

Treatment Implications by Pathogen

Ehrlichia canis / Anaplasma phagocytophilum:

• Doxycycline 10 mg/kg PO q24h × 28 days
• Clinical improvement typically within 24–72 hours of treatment initiation
• Platelet count recovery expected by days 7–14

Borrelia burgdorferi (Lyme):

• Doxycycline 10 mg/kg PO q24h × 28–30 days (joints/systemic)
• For Lyme nephropathy: aggressive supportive care; immunosuppression controversial; prognosis guarded

Babesia canis vogeli:

• Imidocarb dipropionate 6.6 mg/kg IM, two doses 14 days apart
• Atropine pretreatment (0.05 mg/kg SC) to prevent cholinergic effects

Babesia gibsoni:

• Atovaquone 13.3 mg/kg PO q8h + azithromycin 10 mg/kg PO q24h × 10 days (most evidence)
• Imidocarb alone has poor efficacy — PCR species confirmation before treatment is essential

This is why species-level PCR identification matters: giving imidocarb to a *B. gibsoni*-infected dog is inadequate therapy. The diagnostics directly determine the treatment protocol.

Take the Next Step

Tick-borne disease diagnosis in dogs requires both the right tests and the right interpretation framework. Panel PCR testing — delivering simultaneous detection of Ehrlichia, Anaplasma, Borrelia, and Babesia with species-level resolution and quantitative Ct values — is the most clinically complete approach available for acute tick-borne disease presentations.

• Browse CarryOn tick panel and test chips
• Learn how microfluidic chip PCR delivers results in under 60 minutes
• About Ningbo Yinrui Biomedical — veterinary diagnostic equipment manufacturer
• Read our PCR vs ELISA rapid test comparison guide
• Request a demo or distributor inquiry